| Zika Virus Disease and Turkey: Is the Threat Over? | Haluk ERAKSOY | 1–1 |
| Management of Chronic Hepatitis C Virus Infection: A Consensus Report of the Study Group for Viral Hepatitis of the Turkish Society of Clinical Microbiology and Infectious Diseases-2017 Update | Ali ASAN, Neşe DEMİRTÜRK, Neşe SALTOĞLU, Murat SAYAN, Alper ŞENER, Serkan ÖNCÜ, Bilgehan AYGEN, Safiye KOÇULU, Saadet YAZICI, Deniz ÖZKAYA, Haluk ERAKSOY, Derya KETEN, Süda TEKİN, Yunus GÜRBÜZ, Nesrin TÜRKER, Nazan TUNA, Kaya SÜER, Dilara İNAN | 2–36 |
| Zika Virus Disease: The Situation in Turkey and a Review of the Worldwide Outbreak | Tuğba SARI | 2–8 |
| New Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C | Necla TÜLEK | 5–5 |
| A New Endemic Province of Crimean-Congo Haemorrhagic Fever in Turkey: Aydin | Mevlüt TÜRE, Sevin KIRDAR, M. Bülent ERTUĞRUL, Çetin TURAN, Ş. Barçın ÖZTÜRK | 9–14 |
| Analysis of HIV/AIDS-Related Stigma and Discrimination in Turkey: Results of the People Living With HIV Stigma Index | Şebnem ÇALIK, Pınar ÖKTEM, Deniz GÖKENGİN | 15–21 |
| Distribution and Antimicrobial Resistance of Salmonella Serovars Isolated in Kayseri Region | Aycan GÜNDOĞDU, Ayşegül KILIÇ ULU, Hüseyin KILIÇ, Zeynep TÜRE, Ömür Mustafa PARKAN | 22–26 |
| The Distribution of Causative Microorganisms in Diabetic Foot Infection: Has There Been Any Alterations? | Mevlüt TÜRE, Güliz GÜLEÇ UYAR, Selçuk BAKTIROĞLU, M. Bülent ERTUĞRUL, Esra ÇÖREKLİ | 27–31 |
| The Distribution and Antimicrobial Susceptibility Profiles of Etiologic Agents Isolated From Bacteremia Episodes Among Immunocompromised Patients | Mehtap OK AKÇİL, Özlem AZAP KURT, Melike Hamiyet DEMİRKAYA, Ayşegül YEŞİLKAYA | 32–35 |
| Successful Management of Chronic Hepatitis C Patient With Telaprevir-Associated Rash by Switching to Boceprevir | Rezan HARMAN, Elif HORASAN, Elif YILDIRIM | 41–42 |
| Atypical Acute Q Fever: A Case Report | Tuğba SARI, Fatih TEMOÇİN, Hatice KÖSE | 43–45 |
|